Global Congenital Heart Disease Market By Type (Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Others), Diagnosis (Electrocardiogram, Chest X-ray, Echocardiogram, Transoesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac CT Scan or MRI, Cardiac Catheterization, Other), Treatment (Medications, Surgery, Watchful Waiting, Others), Route of Administration (Oral, Parenteral, Others), End Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
Congenital Heart Disease Market Analysis and Size
Congenital heart disease, also called congenital heart defect, is the condition of having one or more abnormalities in heart structure from birth time. Symptoms of congenital heart diseases include shortness of breath, arrhythmias, cyanosis, edema, and tiring quickly upon exertion.
Data Bridge Market Research analyses that the global congenital heart disease market which was USD 4,110.00 million in 2022 is expected to reach USD 8,320.00 million by 2030, and is expected to undergo a CAGR of 9.1% during the forecast period 2023-2030. “Heart Valve Defects” dominates the application segment of the global congenital heart disease market owing to the growing prevalence of cancer and rising research and development in cancer diagnostics and therapeutics. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Congenital Heart Disease Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Others), Diagnosis (Electrocardiogram, Chest X-ray, Echocardiogram, Transoesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac CT Scan or MRI, Cardiac Catheterization, Other), Treatment (Medications, Surgery, Watchful Waiting, Others), Route of Administration (Oral, Parenteral, Others), End Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbott Laboratories (U.S.), AstraZeneca Plc (U.K.), Becton Dickson & Co. (U.S.), Bio-Rad Laboratories (U.S.), Boston Scientific Corp. (U.S.), Laboratory Corporation of America Holdings (LabCorp) (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Glaxosmithkline Plc (U.K.) Janssen Pharmaceuticals, Inc. (U.S.), Medtronic – Ireland, Viatris Inc. (U.S.) Novartis Ag (Switzerland), Pfizer, Inc. (U.S.), Randox Laboratories Ltd. (U.K.), Response Biomedical Corporation (Canada), Sanofi S.A. (France), Siemens Healthineers (Germany), Thermo Fisher Scientific Inc. (U.S.), Vericel Corporation (U.S.)
|
|
Market Opportunities
|
|
Market Definition
The congenital heart disease refers to the economic ecosystem surrounding the diagnosis, treatment, and management of heart defects present at birth. It encompasses medical devices, pharmaceuticals, diagnostic tools, surgical interventions, and healthcare services specific to congenital heart conditions. This market addresses the needs of patients, healthcare providers, and other stakeholders in delivering effective care for individuals with congenital heart disease.
Global Congenital Heart Disease Market Dynamics
Drivers
- Increasing Prevalence
The rising prevalence of congenital heart disease globally is a significant driver for the market. Improved diagnostic techniques, increased awareness, and better access to healthcare services have contributed to identifying more cases, leading to a larger patient population.
- Increasing Focus on Pediatric Cardiology
The growing emphasis on pediatric cardiology and specialized care for children with congenital heart disease drives the market. Pediatric cardiology centers, dedicated research and development efforts, and the availability of pediatric-specific medical devices contribute to market growth.
Opportunities
- Interventional Cardiology Advancements
Advancements in interventional cardiology techniques, such as Tran’s catheter interventions and hybrid procedures, provide opportunities for minimally invasive treatment options. These procedures can reduce the need for open-heart surgeries and improve patient outcomes.
- Increased Use of Pediatric Cardiac Devices
The development of specialized cardiac devices designed specifically for pediatric patients with congenital heart disease presents opportunities. These devices can cater to the unique anatomical and physiological characteristics of children, leading to better outcomes and improved quality of life.
Restraints/Challenges
- Complexity of Treatment
CHD encompasses a wide range of conditions, each with its unique complexities. This complexity makes the development of standardized treatment approaches challenging, as therapies often need to be tailored to individual patients. This can limit the scalability and cost-effectiveness of treatments.
-
High Treatment Costs
Treating congenital heart disease, especially complex cases, can be expensive. High treatment costs may pose a barrier to access for some patients and create financial challenges for healthcare systems and insurance providers.
This global congenital heart disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global congenital heart disease market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In June 2021, Abbott launched Amplatzer Piccolo Occluder in India to treat Congenital Heart defects in premature babies. This has helped the company to expand its product portfolio
- In August 2020 Medtronic received FDA approval for its Harmony Transcatheter Pulmonary Valve (TPV) system. This device is used to treat patients with congenital heart disease who have a dysfunctional right ventricular outflow tract (RVOT) conduit.
Global Congenital Heart Disease Market Scope
The global congenital heart disease market is segmented on the basis of type, diangosis, treatment, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Heart Valve Defects
- Heart Wall Defects
- Blood Vessel Defects
- Others
Diagnosis
- Electrocardiogram
- Chest X-ray
- Echocardiogram
- Transoesophageal Echocardiogram
- Pulse Oximetry
- Exercise Stress Test
- Cardiac CT Scan or MRI
- Cardiac Catheterization
- Other
Treatment
- Medications
- Surgery
- Watchful Waiting
- Others
Route of Administration
- Oral
- Parenteral
- Others
End Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Global Congenital Heart Disease Market Analysis/Insights
The global congenital heart disease market is analysed and market size insights and trends are provided by country, type, diangosis, treatment, route of administration, end users and distribution channel as referenced above.
The countries covered in the global congenital heart disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global congenital heart disease market because of the strong base of healthcare facilities, strong presence of major players in the market, rising demand of the congenital heart disease products and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global congenital heart disease market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global congenital heart disease market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global congenital heart disease market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Congenital Heart Disease Market Share Analysis
The global congenital heart disease market competitive landscape provides details by competitor. details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. the above data points provided are only related to the companies' focus related to global congenital heart disease market.
Some of the major players operating in the global congenital heart disease market are:
- Abbott Laboratories (U.S.)
- AstraZeneca Plc (U.K.)
- Becton Dickson & Co. (U.S.)
- Bio-Rad Laboratories (U.S.)
- Boston Scientific Corp. (U.S.)
- Laboratory Corporation of America Holdings (LabCorp) (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Glaxosmithkline Plc (U.K.)
- Janssen Pharmaceuticals, Inc. (U.S.)
- Medtronic – Ireland
- Viatris Inc. (U.S.)
- Novartis Ag (Switzerland)
- Pfizer, Inc. (U.S.)
- Randox Laboratories Ltd. (U.K.)
- Response Biomedical Corporation (Canada)
- Sanofi S.A. (France)
- Siemens Healthineers (Germany)
- Thermo Fisher Scientific Inc. (U.S.)
- Vericel Corporation (U.S.)
SKU-